For many years, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard first-line treatment for DLBCL; however, pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) has recently emerged as a new treatment option...In addition, agents that have demonstrated efficacy in patients with relapsed or refractory DLBCL-such as the anti-CD19 antibody tafasitamab and immunomodulatory drugs such as golcadomide-are currently under investigation for use in newly diagnosed patients...BsAbs can enable more flexible treatment strategies, including combination regimens with cytotoxic or chemotherapy-free approaches. This review summarizes recent advances and ongoing trials that are investigating novel therapeutic strategies for newly diagnosed DLBCL that may soon be incorporated into clinical practice.

7 days ago

Review • Journal

CD20 (Membrane Spanning 4-Domains A1)

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)

15d

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse (clinicaltrials.gov)

P2, N=65, Recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Oct 2027 --> Dec 2028 | Trial primary completion date: Jan 2026 --> Mar 2027

15 days ago

Trial completion date • Trial primary completion date

golcadomide (CC-99282)

23d

Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas (clinicaltrials.gov)

P1, N=18, Not yet recruiting, Allison Winter

23 days ago

New P1 trial

BCL2 (B-cell CLL/lymphoma 2)

Rituxan (rituximab) • pemetrexed • dexamethasone • golcadomide (CC-99282)

Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)

P1/2, N=58, Not yet recruiting, City of Hope Medical Center

1 month ago

New P1/2 trial

Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)

2ms

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy (clinicaltrials.gov)

P1/2, N=0, Withdrawn, University of Pittsburgh | N=30 --> 0 | Not yet recruiting --> Withdrawn

2 months ago

Enrollment change • Trial withdrawal

Opdivo (nivolumab) • golcadomide (CC-99282)

2ms

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma (clinicaltrials.gov)

P2, N=33, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

2 months ago

Enrollment closed

Gazyva (obinutuzumab) • golcadomide (CC-99282)

2ms

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (clinicaltrials.gov)

P1/2, N=85, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting

2 months ago

Enrollment closed

ALK (Anaplastic lymphoma kinase)

ALK positive • ALK negative

golcadomide (CC-99282)

4ms

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma (clinicaltrials.gov)

P1, N=18, Recruiting, Nathan Denlinger | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

4 months ago

Trial completion date • Trial primary completion date

clonoSEQ®

Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)

4ms

GOLSEEK-1: Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (clinicaltrials.gov)

P3, N=850, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting

4 months ago

Enrollment closed

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • golcadomide (CC-99282)

4ms

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas (clinicaltrials.gov)

P1/2, N=49, Recruiting, The Lymphoma Academic Research Organisation | Not yet recruiting --> Recruiting

4 months ago

Enrollment open

azacitidine • golcadomide (CC-99282) • roginolisib (IOA-244)

5ms

Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment (clinicaltrials.gov)

P1, N=29, Completed, Celgene | Recruiting --> Completed

5 months ago

Trial completion

golcadomide (CC-99282)

5ms

GOLSEEK-2: A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (clinicaltrials.gov)

P2, N=90, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting

5 months ago

Enrollment closed

Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • prednisone • bendamustine • golcadomide (CC-99282)